When: Thursday, September 22, 2022, 5:00 PM - 6:30 PMWhere: Hybrid Event - Perrin LT, Whitechapel/MS Teams, Whitechapel
Speaker: Prof Klaus Schmierer and Prof Angray Kang
Join us for the next FMD Inaugural Lectures to celebrate the work of Prof Klaus Schmierer and Prof Angray Kang
You are invited to join the next event in the FMD Inaugural Lecture series with Prof Klaus Schmierer (Blizard Institute) and Prof Angray Kang (Institute of Dentistry). Please note that this is a joint event with two individual lectures followed by a reception.
This is a hybrid event with guests able to attend in person or online.
In neurology, multiple sclerosis (MS) stands out as a highly treatable condition helped by our increasing understanding of its biology, underpinned by the ‘human experiment’ of new interventions. Translation of new knowledge and trial success into impact for people with MS, however, remains challenging. Obstacles include unease about risk, reluctance to adopt new evidence and inequity of access, all aspects that concern the teams I work with.
Professor Schmierer studied medicine at the Free University Berlin before training in neurology at the Charité (Humboldt University Berlin). He completed a ‘non-scientific’ PhD summa cum laude at the Ernst Moritz Arndt-University, Greifswald before taking up postdoctoral research at the interface between MRI & MS neuropathology at the UCL Institute of Neurology, Queen Square from 2001, becoming a Wellcome Intermediate Clinical Fellow in 2004. In 2009, he was awarded a HEFCE Clinical Senior Lectureship leading to appointments at QMUL and Barts Health NHS Trust, where his main focus is currently on investigator-led clinical trials.
Register
With the COVID-19 pandemic and regular testing, antibodies and antigens have become part of every ones vocabulary. Here I will take you on a journey of discovery of how they are made as diagnostics and drugs, when the drugs stop working, how to detect that failure and how we developed and applied our own COVID antibody testing platforms for the BartsMS community
Professor Kang studied Microbiology at the University of London (KCL, BSc) and at the BBSRC Institutes of Food Research Norwich/Babraham Institute and University of East Anglia Mycotoxin Immunoanalysis (PhD), with postdoctoral research in plant molecular biology at Durham University and recombinant antibody research in Sheffield University in the UK, prior to being appointed Assistant Professor in Molecular Biology at The Scripps Research Institute in La Jolla, CA. He returned to London at the University of Westminster in 2005 and joined QMUL in 2011. He has extensive expertise in developing and applying recombinant antibody technologies for basic research, diagnostics and therapeutic applications.